Exclusive supply agreement and license agreement for dietary supplement products, amended April 25, 2024; we receive royalties and product revenue from 4Life.
| Officer | Age | In this role | Source |
|---|---|---|---|
|
Robert Etherington
Also a director
President and Chief Executive Officer
|
59 |
Since 2013
13 years
|
|
|
Morgan R. Brown
Chief Financial Officer
|
57 |
Since 2022
4 years
|
|
|
Mark Mortenson
Chief Science Officer
|
67 |
Since 2013
13 years
|
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Exclusive supply agreement and license agreement for dietary supplement products, amended April 25, 2024; we receive royalties and product revenue from 4Life.
Purchase of senior secured convertible promissory notes (2024 SSCP Notes).
Purchase of 2024 SSCP Notes.
Purchase of 2024 SSCP Notes.
Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.
Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.
Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.
Loading...